The Survival Benefits of Antiretroviral Therapy in South Africa

Michael D. April,1,5 Robin Wood,12,14 Bethany K. Berkowitz,3 A. David Paltiel,12 Xavier Anglaret,15,16,17 Elena Losina,2,3,8,10 Kenneth A. Freedberg,2,3,4,5,6,7,9 and Rochelle P. Walensky2,3,5,6,7,11

1Department of Emergency Medicine, San Antonio Uniformed Services Health Education Consortium, Texas; 2Harvard Medical School, 3Center for AIDS Research, and 4Department of Health Policy and Management, Harvard School of Public Health, Harvard University. 5The Medical Practice Evaluation Center, 6Division of Infectious Diseases, and 7Division of General Medicine, Massachusetts General Hospital, 8Department of Biostatistics and 9Department of Epidemiology, Boston University, and 10Department of Orthopedic Surgery and 11Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, Massachusetts; 12Yale School of Public Health, New Haven, Connecticut; 13Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, and 14Department of Medicine, University of Cape Town, Cape Town, South Africa; 15INSERM, Centre 897, and 16Université Bordeaux Segalen, Bordeaux, France; and 17Programme PAC-CI/ANRS Research Site in Abidjan, Côte d’Ivoire

(See the editorial commentary by Vermund on pages 483–5.)

Background. We sought to quantify the survival benefits attributable to antiretroviral therapy (ART) in South Africa since 2004.

Methods. We used the Cost-Effectiveness of Preventing AIDS Complications–International model (CEPAC) to simulate 8 cohorts of human immunodeficiency virus (HIV)–infected patients initiating ART each year during 2004–2011. Model inputs included cohort-specific mean CD4+ T-cell count at ART initiation (112–178 cells/µL), 24-week ART suppressive efficacy (78%), second-line ART availability (2.4% of ART recipients), and cohort-specific 36-month retention rate (55%–71%). CEPAC simulated survival twice for each cohort, once with and once without ART. The sum of the products of per capita survival differences and the total numbers of persons initiating ART for each cohort yielded the total survival benefits.

Results. Lifetime per capita survival benefits ranged from 9.3 to 10.2 life-years across the 8 cohorts. Total estimated population lifetime survival benefit for all persons starting ART during 2004–2011 was 21.7 million life-years, of which 2.8 million life-years (12.7%) had been realized by December 2012. By 2030, benefits reached 17.9 million life-years under current policies, 21.7 million life-years with universal second-line ART, 23.3 million life-years with increased linkage to care of eligible untreated patients, and 28.0 million life-years with both linkage to care and universal second-line ART.

Conclusions. We found dramatic past and potential future survival benefits attributable to ART, justifying international support of ART rollout in South Africa.

Keywords. HIV; South Africa; highly active antiretroviral therapy.

South Africa’s human immunodeficiency virus (HIV) epidemic is the largest in the world, with 5.6 million HIV-infected persons in 2011, as estimated by the Joint United Nations Programme on HIV/AIDS (UNAIDS) [1]. Of these, roughly 2.6 million met antiretroviral therapy (ART) eligibility criteria in 2012. This number in part reflects the expansion of eligibility criteria from a CD4+ T-cell count of <200 cells/µL to <350 cells/µL in 2011 [2] to include patients with multidrug-resistant (MDR) tu-
berculosis or patients with non-MDR tuberculosis and a CD4+ T-cell count of <350 cells/µL in 2010 [3]. Yet, despite impres-
sive commitments to expand access to ART [4], one-third (800,000) of these eligible individuals remained without treat-
ment. Meanwhile, current economic challenges have prompted resource-allocation debates that might jeopardize the ongoing treatment of individuals who are already receiving ART and the linkage to care of untreated patients who are eligi-
ble for treatment.

We sought to invigorate discussions of prioritizations for HIV care by quantifying both the cumulative survival benefits of ART since its introduction in South Africa in 2004 [5] and the additional returns that could be obtained via expanded rollout investments. Previous studies provide indirect evidence of the survival benefits conferred by ART in sub-Saharan Africa. During 2001–2011, the estimated number of HIV-in-
ected persons living in sub-Saharan Africa steadily increased from 20.9 million to 23.5 million; during this time horizon, owing to the roll out of ART, annual HIV-related deaths de-
creased by 600,000 (32%) during 2005–2011 [6]. In African countries focused on by the US President’s Emergency Plan for AIDS Relief (PEPFAR), national mortality rates [7] were lower during 2004–2008 compared with nonfocus countries [8]. Comparison of adult life expectancy before and after ART roll-
out in rural KwaZulu Natal revealed an 11.3-year increase [9]. However, to our knowledge, no prior studies have quantified the direct impact of ART rollout on population survival. The objective of our study was to use computer simulation to quan-
tify this impact in South Africa and, by extension, to extrapolate the future survival benefits of further ART rollout.

METHODS

Analytic Overview
Survival benefits attributable to ART in South Africa were esti-
mated using the Cost-Effectiveness of Preventing AIDS Com-
plications–International model of HIV disease and treatment (CEPAC) [10–13]. We defined 8 independent cohorts re-
presenting adult (age, >14 years) HIV-infected persons initiating ART in a given year during 2004–2011. The size of each cohort was derived from UNAIDS reports [1]. These included only persons who initiated therapy in that year. As the simulation progressed, each of these cohorts experienced attrition through mortality and loss to follow-up. No new patients were added to the cohorts after simulation start.

CEPAC simulated the experience of individual HIV-
infected persons; the results of many individual simulations were aggregated to project population-level outcomes. Two simulations were run for each cohort; in one simulation all members initiated ART, and in the other no members initiated ART. Comparison of cohort survival between the ART and no-ART simulations yielded cohort-specific per capita survival benefits attributable to ART. The initial size of each cohort was calculated using published reports of numbers of persons receiving ART each year [1] and ART program retention (Supplementary Materials) [14, 15]. Total survival benefits were calculated by adding the products of per capita survival benefits and initial size of each treated cohort. Benefits were distinguished between those already realized (censored as of December 2012) versus those yet to be realized (censored as of December 2030 and uncensored), given conservative assumptions of no new patients initiating ART after 2011 and no improvements in HIV-related care or ART efficacy.

Model Overview
CEPAC is a state-transition microsimulation model of HIV disease [10–13]. CEPAC simulates each HIV-infected person’s lifetime as a series of monthly transitions between health states representing asymptomatic HIV infection, symptomatic HIV infection, and death. Health states are designed to predict disease progression, as reflected by probabilities of transition to other states. Health states are stratified by prognostic indicators, including HIV disease history (eg, past opportunistic disease), CD4+ T-cell count, and HIV RNA level. HIV RNA level drives the rate of CD4+ T-cell count decline in the absence of treat-
ment [16]. CD4+ T-cell count, in turn, determines the monthly probabilities of developing an opportunistic disease or dying. The monthly risk of HIV-related mortality is generally higher for symptomatic states than for asymptomatic states [17]. There is also a monthly age- and sex-stratified risk of non–HIV-
related death for all individuals [18].

The efficacy of trimethoprim-sulfamethoxazole prophylaxis (which is assumed available to all patients [19]) is modeled as a reduction in the CD4+ T-cell count–dependent risk of opportunistic disease (including bacterial diseases, toxoplasmosis, and pneumocystis). ART efficacy is modeled as a reduction in HIV RNA level with a concomitant increase in CD4+ T-cell count, as well as a resultant decrease in the probabilities of HIV-related death and all opportunistic diseases. In accordance with WHO guidelines, first-line ART failure is defined as the development of a WHO stage 3 or 4 opportunistic disease or a CD4+ T-cell count decrease below either the pre-ART nadir, 100 cells/µL absolute value, or 50% of the peak value [20]. Treatment for patients experiencing first-line therapy failure (defined, in the assumed absence of HIV RNA load monitor-
ing, as onset of an opportunistic disease or achievement of CD4+ T-cell count failure criteria) entailed transition to second-line ART, if available. To reflect treatment resource lim-
itations, the availability of second-line ART for simulated persons in whom first-line therapy failed was limited to the percentage of all ART recipients (2.4%, as reported by the WHO [21]) who were receiving second-line therapy (including those in whom first-line therapy did not fail) in low- and middle-income countries outside of the Americas.
We ran simulations of 1 million patients with and 1 million patients without ART for each cohort to achieve stable per capita survival benefit estimates. Comparison of per capita survival between the simulations with and those without ART yielded cohort-specific per capita survival benefit estimates. The sum of the products of CEPAC-generated per capita survival benefits and numbers of persons initiating ART for each cohort (see cohort size estimates, below) yielded the total number of life-years attributable to ART initiated during 2004–2011 (Supplementary Materials).

Model Inputs
We used data from the Southern African Catholic Bishops Conference cohort to estimate mean age ± SD (37 ± 10 years), sex distribution (33% male), HIV RNA level distributions (46% with an HIV RNA level of >100 000 copies/mL), and mean CD4+ T-cell count at ART initiation (112–178 cells/µL during 2004–2011) of the simulated cohorts [22, 23]. HIV disease natural history parameters, including chronic AIDS mortality and opportunistic disease incidence and mortality, were taken from the Cape Town AIDS Cohort [17]. Non-HIV mortality was estimated using United Nations life tables for South Africa, with adjustment to remove HIV-related mortality [18].

Longitudinal cohort analysis yielded the effect of ART (independent of CD4+ T-cell count rise) on additional reductions in chronic AIDS mortality (56%–96%) and opportunistic disease incidence (32%) [24]. Derived ART efficacy parameters included a 6-month HIV RNA suppression probability of 78% [25], a mean CD4+ T-cell count increase 6 months after ART initiation of 148 cells/µL [26], and a 0.8% monthly probability of virologic rebound after 6 months for those in whom the HIV RNA level was initially suppressed (Table 1) [25].

Cohort Size Estimates
We estimated the number of persons initiating ART each year (ie, the initial size of each cohort), using data from the Joint United Nations Programme on HIV/AIDS (UNAIDS) [1]. These data describe the number of persons receiving ART each year and the total receiving ART during December of a given year but do not specify when they initiated ART. We therefore calculated the difference between the UNAIDS-reported total number of persons receiving ART during December of a given year and the total receiving ART during December of the previous year. This latter number was adjusted downward to reflect attrition due to both loss to follow-up and mortality [14, 15, 27, 28]. In the case of the first cohort, which initiated therapy in 2004, the UNAIDS-reported value was assumed to represent exactly the number of persons initiating ART during that year, because there were no data from earlier reported cohorts to subtract.

Annual cohort attrition comprised losses due to both mortality and loss-to-follow-up as reported by meta-analyses: 18.5%–27.6% during the first year, 8.3%–19.8% during the second year, 5.4%–5.8% during the third year, and 2.6%–2.8% thereafter (Supplementary Table 1) [14, 15, 27, 28]. These base-case retention loss estimates exceed those reported by various South African cohorts with 5–6 years of follow-up data [29,

<table>
<thead>
<tr>
<th>Model Parameter</th>
<th>Base-Case Value</th>
<th>Range Examined</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohort characteristica</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y, mean ± SD [22, 23]</td>
<td>37 ± 10</td>
<td>. . .</td>
</tr>
<tr>
<td>Male sex, subjects, % [22, 23]</td>
<td>33</td>
<td>. . .</td>
</tr>
<tr>
<td>CD4+ T-cell at ART initiation, cells/µL, mean ± SD [22, 23]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>112 ± 95</td>
<td>38–157</td>
</tr>
<tr>
<td>2005</td>
<td>127 ± 124</td>
<td>38–172</td>
</tr>
<tr>
<td>2006</td>
<td>133 ± 133</td>
<td>46–178</td>
</tr>
<tr>
<td>2007</td>
<td>145 ± 143</td>
<td>51–189</td>
</tr>
<tr>
<td>2008</td>
<td>149 ± 132</td>
<td>52–197</td>
</tr>
<tr>
<td>2009</td>
<td>156 ± 147</td>
<td>56–197</td>
</tr>
<tr>
<td>2010</td>
<td>178 ± 345</td>
<td>70–232</td>
</tr>
<tr>
<td>2011</td>
<td>173 ± 144</td>
<td>73–230</td>
</tr>
<tr>
<td>Initial HIV RNA level, patients, % [22, 23]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;100 000 copies/mL</td>
<td>46</td>
<td>. . .</td>
</tr>
<tr>
<td>30 001–100 000 copies/mL</td>
<td>33</td>
<td>. . .</td>
</tr>
<tr>
<td>10 001–30 000 copies/mL</td>
<td>21</td>
<td>. . .</td>
</tr>
<tr>
<td>&lt;10 001 copies/mL</td>
<td>0</td>
<td>. . .</td>
</tr>
<tr>
<td>Disease natural history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monthly risk of AIDS-attributable death without ART, patients, %, by CD4+ T-cell countb [17]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–50 cells/µL</td>
<td>4–10</td>
<td>. . .</td>
</tr>
<tr>
<td>51–100 cells/µL</td>
<td>2–5</td>
<td>. . .</td>
</tr>
<tr>
<td>101–200 cells/µL</td>
<td>1–3</td>
<td>. . .</td>
</tr>
<tr>
<td>201–350 cells/µLc</td>
<td>0</td>
<td>. . .</td>
</tr>
<tr>
<td>351–500 cells/µLc</td>
<td>0</td>
<td>. . .</td>
</tr>
<tr>
<td>&gt;500 cells/µLc</td>
<td>0</td>
<td>. . .</td>
</tr>
<tr>
<td>Antiretroviral therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ART efficacy, 2 lines (NNRTI + 2 NRTIs and PI + 2 recycled NRTIs)P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV RNA suppression at 6 mo, patients, % [25]</td>
<td>78</td>
<td>54–97</td>
</tr>
<tr>
<td>CD4+ T-cell count increase at 6 mo, cells/µL, mean [26]</td>
<td>148</td>
<td>102–225</td>
</tr>
<tr>
<td>Monthly risk of ART failure after 6 mo once suppressed, % [25]</td>
<td>0.8</td>
<td>0.4–0.9</td>
</tr>
<tr>
<td>Second-line ART availability, all patients receiving ART, % [21]</td>
<td>2.4</td>
<td>0–4.8</td>
</tr>
<tr>
<td>ART program retention at 12 mo, patients, %d [14, 15, 27, 28]</td>
<td>72.4–81.5</td>
<td>63.8–81.5</td>
</tr>
</tbody>
</table>

| Abbreviations: NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor |
| a Model inputs were derived from additional analysis of the primary dataset on which the cited papers reported. |
| b Ranges reflect distributions of base-case inputs, based on each person’s history of opportunistic disease. |
| c Input values are nonzero but are reported as zero because of rounding. |
| d Ranges reflect value differences in retention for each of the 8 cohorts (see Methods). |

Downloaded from https://academic.oup.com/jid/article-abstract/209/4/491/2193632 by guest on 11 April 2019
In subsequent years (2005–2011), the numbers of persons assigned to start in each cohort were calculated such that the number of persons alive across all cohorts summed to UNAIDS-reported numbers of persons receiving ART in South Africa each year [1]. In this way, we ensured that the model cohort sizes never exceeded the numbers of persons reported to be receiving ART by UNAIDS data. After the eighth cohort initiated treatment, in 2011, no additional persons were added to care receiving ART by UNAIDS data. After the eighth cohort initiated treatment, in 2011, no additional persons were added to care receiving ART by UNAIDS data. The latter scenarios assumed that 34% of eligible patients were linked to care each year. Maximum potential benefits from increased linkage to care were projected by examining alternative annual rates of linkage to care up to 84% [39].

### Sensitivity Analyses

We conducted sensitivity analyses to examine the impact of uncertainty in base-case parameter input values (Table 1) and assumptions on projected survival benefits. These analyses included alternative inputs reflecting uncertainty in numbers of persons initiating ART each year [1], mean CD4⁺ T-cell count upon ART initiation [22, 23], CD4⁺ T-cell count and HIV RNA level monitoring availability [20, 31, 32], ART efficacy [26, 33–37], second-line ART availability [21], and ART program retention (Supplementary Materials) [14, 15]. We also simultaneously changed all of these variables to generate best- and worst-case scenarios reflecting uncertainty in all base-case inputs.

### Additional Analyses

Additional analyses examined outcomes through 2030 for scenarios in which prospective policy decisions accelerate the roll out of HIV treatment services as of January 2014. These scenarios included universal access to second-line ART (rather than the base-case 2.4% availability) and future annual linkage to care of eligible HIV-infected persons not yet receiving ART. The latter scenarios assumed that 34% of eligible patients were not yet receiving ART [1], that the HIV-infected population size grew according to the projections by the Actuarial Society of South Africa [38], and that 10% of untreated eligible patients were linked to care each year. Maximum potential benefits from increased linkage to care were projected by examining alternative annual rates of linkage to care up to 84% [39].

### RESULTS

#### Survival Benefits

The number of persons initiating ART each year grew from 50 100 in 2004 to 557 300 in 2011. In total, 2 222 700 individuals were estimated to have initiated ART during 2004–2011. Regarding censored survival benefits, the cohort initiating ART in 2004 had an estimated per capita life expectancy of 1.9 years in the simulation without ART, compared with 5.9 years in the simulation with ART, for a per capita increase of 4.0 life-years. Censored per capita survival benefits decreased for subsequent cohorts, with a low of 0.2 life-years for the cohort initiating ART in 2011. The sum of products of the numbers of patients newly initiating ART and the censored per capita survival benefits yielded an estimated 2.8 million life-years as of December 2012 (Table 2).

Regarding lifetime (uncensored) survival benefits, the cohort initiating ART in 2004 had an estimated per capita life expectancy of 1.9 years in the simulation without ART, compared with 11.2 years in the simulation with ART, for a per capita increase of 9.3 years. Censored survival benefits decreased for subsequent cohorts, with a low of 0.2 lifetime years for the cohort initiating ART in 2011. The sum of products of the numbers of patients newly initiating ART and the censored per capita survival benefits yielded an estimated 2.8 million lifetime years as of December 2012 (Table 2).
of 9.3 life-years. Per capita survival benefits for subsequent cohorts were comparable, ranging from 9.3 to 10.2 life-years. The sum of products of the numbers of patients newly initiating ART and the lifetime per capita survival benefits yielded an estimated 21.7 million life-years (Table 2). Of this expected total, 18.9 million life-years (87.3%) had yet to be attained.

**Univariate Sensitivity Analyses**
Univariate sensitivity analyses demonstrated that the base-case lifetime survival benefit estimate (21.7 million life-years) was most sensitive to uncertainty regarding ART efficacy (probability of initial viral suppression, CD4+ T-cell count rise, and probability of late ART failure), yielding lifetime survival benefits ranging from 14.0 to 35.4 million life-years. Lifetime survival benefits were also sensitive to ART program retention (17.4–23.0 million life-years) and numbers of persons receiving ART (19.7–23.7 million life-years). Lifetime survival benefits were comparatively insensitive to the WHO monitoring guidelines followed for guiding the transition to second-line ART, uncertainty in the availability of second-line ART, and CD4+ T-cell count at ART initiation (Figure 1).

**Best- and Worst-Case Scenarios**
All ranges of values used in the univariate analyses were used simultaneously in a multivariable analysis to establish worst- and best-case scenarios reflecting uncertainty in all variables listed in Figure 1. In the worst-case scenario, lifetime survival benefits reached 10.2 million life-years, of which 2.2 million life-years (21.8%) had already been realized as of December 2012. The best-case scenario resulted in lifetime survival benefits of 37.6 million life-years, of which 3.0 million (8.1%) had already been realized.

**Prospective Policy Analyses Projections to 2030**
Additional analyses examined hypothetical scenarios of implementing various policy initiatives associated with HIV treatment and linkage to care in January 2014, projected to December 2030 (Figure 2). The base-case survival benefits were projected to reach 17.9 million life-years. A scenario of universal access to second-line ART starting in January 2014 increased these benefits to 21.7 million life-years. Implementation of annual linkage to care of 10% of eligible untreated HIV-infected patients yielded 23.3 million life-years. Finally, universal access to second-line ART coupled with expanded case detection yielded 28.0 million life-years.

**Maximum Potential Benefits**
Additional analyses demonstrated the sensitivity of these future projections through December 2030 to the annual proportion of untreated HIV-infected persons assumed to be linked to care each year with expanded testing (Figure 3). Survival benefits plateau with increasing linkage-to-care rates; at higher rates nearly all eligible patients are ultimately linked to care and so additional rate increases do not increase numbers of patients ultimately receiving ART but rather only achieve earlier ART initiation. In a scenario of increased linkage to care only and base-case availability of second-line ART for no more than 2.4%
of ART recipients at any given time, survival benefits as of 2030 reached 25.9 million life-years with 20% linkage to care and up to 29.4 million life-years with 84% linkage to care. In a scenario of universal access to second-line ART starting in 2014, survival benefits as of 2030 reached 31.2 million life-years with 20% linkage to care and up to 35.6 million life-years with 84% linkage to care.

**DISCUSSION**

We provide a model-based estimate of the survival benefits attributable to ART in South Africa. In the base case, 21.7 million life-years were attributable to ART over the lifetime of all persons initiating ART during 2004–2011, of which only 2.8 million life-years (12.7%) had been realized as of December 2012. Implementation of expanded testing and treatment policies starting in 2014 were projected to significantly increase these benefits. By 2030, survival benefits will reach 17.9 million life-years under current policies, assuming no new patients initiate ART. This is only 82% of the potential benefits with universal second-line ART access (21.7 million life-years), 77% of the benefits with annual linkage to care of 10% of untreated eligible patients (23.3 million life-years), and 50% of the potential benefits with annual linkage to care of 84% of untreated eligible patients and universal second-line ART access (35.6 million life-years).

This study contributes to a growing literature establishing the profound survival benefits resulting from investments in the global response to the HIV pandemic [8, 40, 41]. Approximately $13.7 billion was invested in 2008 alone, including 31% from direct bilateral funding (namely PEPFAR), 12% from multilateral institutions (including the Global Fund), and 5% from philanthropic sources, such as the Bill and Melinda Gates Foundation [27, 42]. These investments have already saved millions of life-years, but this analysis highlights that little more than one-tenth of the survival benefits made possible by current policies have been realized in South Africa. Furthermore, these benefits may be substantially increased through more-aggressive linkage to care of untreated eligible HIV-infected patients and expansion of access to second-line ART. Realizing the full potential return on investments already made will require that funding sources remain committed to maintaining and expanding resources available for monitoring, retention, and treatment.
Our univariate sensitivity analyses highlight the principal sources of uncertainty in quantifying population survival gains attributable to ART during 2004–2011. However, because survival gains are calculated as the difference in survival between a cohort receiving ART and an identical cohort not receiving ART, sensitivity analyses of parameters informing population characteristics (eg, CD4+ T-cell count) are not comparisons of alternative ART initiation policies. Instead, these results represent a measure of the impact on survival gain estimates of the uncertainty in the mean CD4+ T-cell counts of all HIV-infected patients initiating ART in South Africa during 2004–2011. Indeed, while cohort data from sub-Saharan Africa demonstrate that ART initiation at higher CD4+ T-cell counts results in increased survival [43], our results demonstrate the relative insensitivity of survival gains to the cohort mean CD4+ T-cell count. The limited impact of CD4+ T-cell count at ART initiation reflects a counterbalancing of increased survival in the treatment scenario by increased survival in the counterfactual scenario without ART.

The results of this study reflect an intentionally conservative estimate of survival benefits attributable to ART in South Africa. The base-case scenario assumed that no additional persons enrolled in ART beyond those already being treated as of the end of 2010, that no improvement in ART efficacy occurred, and that second-line ART availability was limited to 2.4% of all persons being treated with ART. The analyses of more-frequent testing and more-comprehensive treatment policies demonstrate dramatic increases in survival benefits when these unfavorable assumptions are relaxed, with the potential to more than double the survival benefits under current policies by 2030 in the most-expanded linkage to care and treatment scenarios.

Our analysis demonstrates substantial survival benefits in a scenario of future increased linkage to care of untreated HIV-infected persons eligible for ART but not yet receiving treatment [44]. Indeed, the UNAIDS estimates that one-third of HIV-infected persons living in South Africa who are eligible for ART are not yet receiving treatment [1], posing an opportunity to expand access to life-extending medication [11, 45]. Such expansion will require 2 components. First, expanded case detection through HIV testing will be necessary; national surveys suggest that half of South Africans have never been tested for HIV [46]. Second, as case detection increases, larger numbers of HIV-infected persons will be identified before they are eligible for ART, and so it will become increasingly important to track and monitor these persons until they are eligible for ART. Furthermore, our sensitivity analyses illustrate that the rate at which untreated eligible patients are linked to care drives survival benefits, demonstrating the impact of speed of scale-up on survival [13]. Base-case survival benefits as of 2030 range from 17.9 million life-years without linkage to care of any additional patients to 29.4 million life-years with immediate linkage to care of 84% of untreated patients eligible for ART each year.

This analysis has several limitations. First, the total survival benefit estimates relied on the accuracy of UNAIDS data on the numbers of persons receiving ART each year [1]. Second, the model does not capture the benefits of preventing secondary transmission. Third, our analysis considers only adults, neglecting survival benefits attributable to prevention of mother-to-child transmission [47] and treatment of HIV-infected children [48]. Finally, our future survival gain projections to 2030 and beyond rely on many assumptions, including predictable epidemic growth, stable health and demographic characteristics of ART recipients, consistent HIV treatment policy and ART program performance, reliable treatment-funding sources, and stable treatment efficacy. To the extent that any of these assumptions do not reflect reality, our projections regarding the future benefit of ART and ART policy changes would differ accordingly.

Since emerging as the epicenter of the HIV pandemic in the early 1980s, South Africa has endured devastating losses, with AIDS-related deaths exceeding 200 000 persons each year since 2001 [1]. These deaths have undermined families, societies, and economies throughout the country. This analysis highlights the dramatic capacity for HIV treatment to stem this tide of disease in South Africa, projecting 2.8 million years of life already gained. That said, this analysis finds that the lifetime survival
benefits attributable to ART in South Africa by 2030 range from 17.9 million life-years under current treatment policies up to 35.6 million with a combination of aggressive linkage to care and unrestricted second-line ART availability. Realization of these future potential benefits will require not only drugs but also commitment by the international community to continue implementing and refining effective treatment programs and practices.

Supplementary Data

Supplementary materials are available at The Journal of Infectious Diseases online (http://jid.oxfordjournals.org/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyrighted. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Acknowledgments. We thank Eric Ross, for his contributions to the analysis of the simulation data; and Dr Carl Marrow, for his analysis of data from the Southern African Catholic Bishops Conference cohort.

Dr April had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs April, Walensky, Wood, and Anglaret were involved in the study concept and design. Drs April, Wood, Anglaret, and Berkowitz were involved in data acquisition. Drs April, Walensky, Berkowitz, Wood, Paltiel, Losina, Freedberg, and Anglaret were involved in the analysis and interpretation of data. Dr April was involved in manuscript drafting. Drs April, Walensky, Wood, Berkowitz, Paltiel, Losina, Freedberg, and Anglaret were involved in manuscript revision. Drs April, Losina, Berkowitz, Walensky, and Paltiel were involved in statistical analysis. Drs Walensky, Paltiel, Freedberg, Losina, Wood, and Anglaret were involved in obtaining funding. Drs April and Berkowitz were involved in providing administrative, technical, or material support. Drs April, Walensky, Paltiel, and Losina were involved in study supervision.

Disclaimer. The view(s) expressed herein are those of the authors and do not reflect the official policy or position of Brooke Army Medical Center, the US Army Medical Department, the US Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the US government. The funding sources had no role in the design, analysis, or interpretation of the study or in the decision to submit the manuscript for publication.

Financial support. This work was supported by the National Institute of Allergy and Infectious Diseases (grants R01 AI058736, P30 AI060354, and R01 AI093269) and the Infectious Diseases Society of America (grants R01 AI058736, P30 AI060354, and R01 AI093269) and the Infectious Diseases Society of America (grants R01 AI058736, P30 AI060354, and R01 AI093269) and the Infectious Diseases Society of America (grants R01 AI058736, P30 AI060354, and R01 AI093269) and the Infectious Diseases Society of America (grants R01 AI058736, P30 AI060354, and R01 AI093269) and the Infectious Diseases Society of America (grants R01 AI058736, P30 AI060354, and R01 AI093269) and the Infectious Diseases Society of America (grants R01 AI058736, P30 AI060354, and R01 AI093269) and the Infectious Diseases Society of America (grants R01 AI058736, P30 AI060354, and R01 AI093269)

Potential conflict of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References


